Toronto-based biotech company Awakn Life Sciences has announced it is expanding a ketamine study to focus on four behavioural addictions.
Story continues below
This advertisement has not loaded yet, but your article continues below.
The study, first announced in August , was initially focused on gambling disorder but will now include binge eating disorder, compulsive sexual behaviour and internet gaming disorder.
The study will be led by Celia Morgan, professor of psychopharmacology at the University of Exeter, U.K. and Awakn’s head of ketamine-assisted therapy for addiction.
According to a news release, the study will explore and monitor whether the ketamine can increase neuroplasticity using EEG (Electroencephalogram) and attempt to “harness a window in which the brain is able
Read full article on The Growth Op
